|
Welcome
|
|
11 February 2012
|
|
|
| home | my details | ISRCTN Register | mRCT | links | information | news |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
|
| [ ...Back to search results ] | [ Print-friendly version ] |
| A randomised controlled study to assess the emotional needs and efficacy of a service to meet identified emotional needs of individuals with macular disease |
| Source of record | UK Trials |
| ISRCTN | ISRCTN43918552 |
| Date ISRCTN assigned | 06/11/2007 |
| Local reference number(s) | Version 1, 27th July 2007 |
| Public title | A randomised controlled study to assess the emotional needs and efficacy of a service to meet identified emotional needs of individuals with macular disease |
| Scientific title | |
| Acronym | N/A |
| Disease/condition/study domain | Age related macular disease |
| Study hypothesis | To compare the emotional wellbeing of individuals newly registered as sight impaired with macular disease who have access to an emotional support package of care together with current standard care, with those who only receive the current standard care. The hypothesis is that the additional care group will experience less psychological pathology (anxiety and depression) and higher quality of life compared to the 'standard care' group. Primary objective is to assess the efficacy of an emotional support service for individuals who are visually impaired. Secondary objectives include: 1. To assess the emotional needs of individuals with macular disease over the 12 months following registration as sight impaired 2. To identify factors that predict individuals who are experiencing emotional difficulties adjusting to registration 3. To use the findings of the study to inform an update of the Certificate of Visual Impairment (CVI) form |
| Design/methodology | Randomised controlled trial |
| Research ethics review | Ethics approval pending from the Devon and Torbay Research Ethics Committee as of 24/09/2007. |
| Countries of trial | United Kingdom |
| Participants - inclusion criteria | 1. Patients who are experiencing sight impairment through Age related Macular Disease (AMD) that requires initial registration as sight impaired 2. Voluntary informed consent given |
| Participants - exclusion criteria | 1. Limited understanding of English 2. Diagnosis of dementia 3. Have severe learning disabilities 4. Have a current severe psychiatric illness 5. Sight impairment for reasons other than macular disease 6. Unable to give voluntary informed consent |
| Patient information material | |
| Anticipated start date | 01/10/2007 |
| Anticipated end date | 31/01/2011 |
| Status of trial | Ongoing |
| Target number of participants | 128 |
| Interventions | All patients (both intervention and control groups) will have current standard care plus an initial assessment via completion of questionnaires and an interview administered via the psychology service. Each of the participants in the intervention group will be allocated to a volunteer who also has a macular disease. The participants will then receive a telephone call from the volunteers they are assigned to, inviting them to attend a 'newly diagnosed' group meeting run by volunteers with macular disease. Key activities of the newly diagnosed group: The group aims to: 1. Provide information: 1.1. Answer questions about macular disease from volunteers' own experiences 1.2. Distribute information (leaflets, audio tapes, etc.,) regarding macular disease, the low vision clinic, support services, benefits, etc., 1.3. Describe, invite to and answer questions about the Macular Disease Support Group 2. Screen individuals for evidence of unmet needs: 2.1. Those who are in low mood, extremely anxious 2.2. Those who need but are not obtaining available social service support 2.3. Those not accessing appropriate medical services, e.g., low vision clinic 3. Provide a link between newly diagnosed individuals and the professional and voluntary services: 3.1. Relay questions that they could not answer to the ophthalmologist, social services, clinical psychology, etc., as relevant and ensure that the answer is fed back to the questioner 3.2. Relay details of those requiring additional support to either the ophthalmology service, social services or clinical health psychology service as appropriate |
| Primary outcome measure(s) | Psychological pathology, measured at baseline, 4 and 12 months: 1. Psychiatric status, assessed by the 28-item General Health Questionnaire (GHQ-28) 2. Hospital Anxiety and Depression Scale (HADS) 3. Risk of deliberate self-harm, assessed by Beck Hopelessness Scale (BHS) |
| Secondary outcome measure(s) | The following secondary outcomes will be measured at baseline, 4 and 12 months: 1. Quality of Life, assessed by the Macular Disease-dependent Quality of Life (MacDQoL) scale 2. Adjustment, assessed by the Impact of Events Scale (IES) 3. Coping strategies, assessed by the COPE questionnaire 4. Social support, assessed by the Social Support Questionnaire (SSQ) 5. Knowledge, support and satisfaction questionnaire |
| Sources of funding | Torbay Medical Research Fund (UK) |
| Sponsor name | South Devon Healthcare NHS Foundation Trust (UK) |
| Sponsor details | Torbay Hospital Lawes Bridge Torquay United Kingdom TQ2 7AA |
| Sponsor email | fiona.roberts@nhs.net |
| Sponsor website | http://www.sdhct.nhs.uk/ |
| Contact name | Dr Barbara Hedge |
| Contact details | Department of Clinical Psychology Torbay Hospital Lawes Bridge Torquay United Kingdom TQ2 7AA |
| Contact email | barbara.hedge@nhs.net |
| More information | For more up-to-date information please go to the ISRCTN link below. |
| Link to record in ISRCTN Register | ISRCTN43918552 |
| Date last extracted from ISRCTN register | 17/04/2008 |
|
|
|
|
|
| © 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement | |
|
|
|
|